Marloes H. ten Brink

High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric <scp>HSCT</scp>: a prospective multicentre study

M. Y. Eileen C. van der Stoep, Alice Bertaina, Marloes H. ten Brink et al. · British Journal of Haematology · 2017 · 44 citations · Full text

Pharmacy, Pediatrics, Pharmacokinetics +14

Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Marloes H. ten Brink, Oliver Ackaert, J. Zwaveling et al. · Therapeutic Drug Monitoring · 2014 · 39 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Effect of Genetic Variants<i>GSTA1</i>and<i>CYP39A1</i>and Age on Busulfan Clearance in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Marloes H. ten Brink, Tom van Bavel, Jesse J. Swen et al. · Pharmacogenomics · 2013 · 34 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT

Marloes H. ten Brink, J. Wessels, Jan den Hartigh et al. · Bone Marrow Transplantation · 2011 · 31 citations

Life Sciences, Hematology, Pharmacokinetics +12

Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients

Marloes H. ten Brink, Jesse J. Swen, Stefan Böhringer et al. · Pharmacogenetics and Genomics · 2013 · 22 citations

Pharmacy, Pharmacokinetics, Pharmacology +16